Studies in models of aging and AD have shown that long-term melatonin supplementation limits neurodegeneration, improves cognitive function, reduces Aβ deposition and tau phosphorylation, and inhibits microglial activation and inflammatory cytokine expression [7,138]. The gene discussed is MAPT; the disease is Alzheimer disease.